Kathryn Shaw‐Saliba
A5001429660- SARS-CoV-2 and COVID-19 Research
- Influenza Virus Research Studies
- COVID-19 Clinical Research Studies
- Respiratory viral infections research
- Long-Term Effects of COVID-19
- SARS-CoV-2 detection and testing
- Mosquito-borne diseases and control
- Malaria Research and Control
- Animal Disease Management and Epidemiology
- Viral Infections and Outbreaks Research
- Pneumonia and Respiratory Infections
- Vaccine Coverage and Hesitancy
- COVID-19 epidemiological studies
- Biosensors and Analytical Detection
- Hepatitis B Virus Studies
- Immune responses and vaccinations
- HIV Research and Treatment
- Diabetes and associated disorders
- Infection Control in Healthcare
- COVID-19 diagnosis using AI
- Vector-borne infectious diseases
- Data-Driven Disease Surveillance
- COVID-19 Impact on Reproduction
- Disaster Response and Management
- Peptidase Inhibition and Analysis
National Institute of Allergy and Infectious Diseases
2021-2025
National Institutes of Health
2022-2025
Johns Hopkins Medicine
2018-2024
Johns Hopkins University
2013-2024
Government of the United States of America
2022-2023
Australian National University
2022
Bloomberg (United States)
2020
Harvard University
2016-2018
It is unclear why some SARS-CoV-2 patients readily resolve infection while others develop severe disease. By interrogating metabolic programs of immune cells in and recovered coronavirus disease 2019 (COVID-19) compared with other viral infections, we identify a unique population T cells. These express increased Voltage-Dependent Anion Channel 1 (VDAC1), accompanied by gene functional characteristics linked to mitochondrial dysfunction apoptosis. The percentage these increases elderly...
Tecovirimat is available for the treatment of mpox (formerly known as monkeypox) in Europe and United States, on basis findings from efficacy studies animals safety evaluations healthy humans. Evidence randomized, controlled trials patients with lacking. We conducted a double-blind, placebo-controlled trial tecovirimat Democratic Republic Congo (DRC). Patients at least one skin lesion positive polymerase-chain-reaction results clade I MPXV were assigned 1:1 ratio to receive or placebo. All...
In a randomized, placebo-controlled, clinical trial, bamlanivimab, SARS-CoV-2-neutralizing monoclonal antibody, given in combination with remdesivir, did not improve outcomes among hospitalized patients COVID-19 based on an early futility assessment.
Background: Levels of plasma SARS-CoV-2 nucleocapsid (N) antigen may be an important biomarker in patients with COVID-19 and enhance our understanding the pathogenesis COVID-19. Objective: To evaluate whether levels can predict short-term clinical outcomes identify viral factors associated hospitalized SARS-CoV-2. Design: Cross-sectional study baseline level from 2540 participants enrolled TICO (Therapeutics for Inpatients With COVID-19) platform trial August 2020 to November 2021,...
Gametocytes are essential for Plasmodium transmission, but little is known about the mechanisms that lead to their formation. Using piggyBac transposon-mediated insertional mutagenesis, we screened parasites no longer form mature gametocytes, which led isolation of 29 clones (insertional gametocyte-deficient mutants) fail gametocytes. Additional analysis revealed 16 genes putatively responsible loss gametocytogenesis, none has been previously implicated in gametocytogenesis. Transcriptional...
Rapid point-of-care tests (POCTs) for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies vary in performance. A critical need exists to perform head-to-head comparisons these assays.
ABSTRACT Plasmodium vivax chloroquine resistance has been documented in nearly every region where this malaria-causing parasite is endemic. Unfortunately, P. surveillance and drug discovery are challenging due to the low parasitemias of patient isolates poor survival through ex vivo maturation that reduce sensitivity scalability current antimalarial assays. Using cryopreserved from Brazil fresh India, we established a robust enrichment method for parasites. We next performed medium screen...
Several inflammatory cytokines are upregulated in severe coronavirus disease 2019 (COVID-19). We compared COVID-19 versus influenza to define differentiating features of the response these pathogens and their association with disease. Because elevated body mass index (BMI) is a known risk factor for COVID-19, we examined relationship BMI associated
Plasmodium parasites are reliant on the Apicomplexan AP2 (ApiAP2) transcription factor family to regulate gene expression programs. DNA binding domains have no homologs in human or mosquito host genomes, making them potential antimalarial drug targets. Using an in-silico screen dock thousands of small molecules into crystal structure AP2-EXP (Pf3D7_1466400) domain (PDB:3IGM), we identified putative interacting compounds. Four compounds were found block by and at least one additional ApiAP2...
Abstract Background Persistent mortality in adults hospitalized due to acute COVID-19 justifies pursuit of disease mechanisms and potential therapies. The aim was evaluate which virus host response factors were associated with risk among participants Therapeutics for Inpatients (TICO/ACTIV-3) trials. Methods A secondary analysis 2625 SARS-CoV-2 infection randomized 1 5 antiviral products or matched placebo 114 centers on 4 continents. Uniform, site-level collection participant baseline...
The continual emergence of novel influenza A strains from non-human hosts requires constant vigilance and the need for ongoing research to identify that may pose a human public health risk. Since 1999, canine H3 viruses (CIVs) have caused many thousands or millions respiratory infections in dogs United States. While no with CIVs been reported date, these could zoonotic In studies, National Institutes Allergy Infectious Diseases (NIAID) Centers Excellence Influenza Research Surveillance...
Ensovibep (MP0420) is a designed ankyrin repeat protein, novel class of engineered proteins, under investigation as treatment SARS-CoV-2 infection.To investigate if ensovibep, in addition to remdesivir and other standard care, improves clinical outcomes among patients hospitalized with COVID-19 compared care alone.Double-blind, randomized, placebo-controlled, trial. (ClinicalTrials.gov: NCT04501978).Multinational, multicenter trial.Adults COVID-19.Intravenous 600 mg, or placebo.Ensovibep was...
Although antivirals remain important for the treatment COVID-19, methods to assess efficacy are lacking. Here, we investigated impact of remdesivir on viral dynamics and their contribution understanding antiviral in multicenter Adaptive COVID-19 Treatment Trial 1, which randomized patients or placebo.
Abstract Background Low blood absolute lymphocyte count (ALC) may predict severe COVID-19 outcomes. Knowledge gaps remain regarding the relationship of ALC trajectory with clinical outcomes and factors associated lymphopenia. Methods Our post hoc analysis Therapeutics for Inpatients platform trial utilized proportional hazards models to assess relationships between Day (D) 0 lymphopenia (ALC < 0.9 cells/uL), D0 0.5 cells/uL) or D5 mortality secondary infections, sustained recovery using...
Abstract Background InVITE (NCT# 05096091) is a 7-country observational study assessing immune responses to COVID-19 vaccines offered from national vaccination programs. This analysis focuses on the response 2 months after receipt of booster vaccine (third dose) among participants Mexico and Mongolia. Vaccines assessed were mRNA (Comirnaty, Pfizer (BioNTech), non-replicating viral vector (Vaxzevria, Oxford/AstraZeneca; Sputnik-V, Gam-COVID-Vac), or inactivated virus (CoronaVac, SinoVac...
The impact on immunogenicity and efficacy of SARS-CoV-2 vaccination in people with prior COVID-19 could differ depending timing number doses. VATICO study randomized 66 hospitalized recovered individuals to receive either immediate or deferred vaccination, one two doses mRNA vaccines. We measured binding neutralizing antibodies against at enrollment longitudinally. Median (IQR) time from infection first was 68 (53–75) days the group, 151 (137–173) group. At week 48, vaccine did not influence...
Plasmodium vivax, the most widely distributed human malaria parasite, is restricted to reticulocytes, limiting its asexual proliferation. In recent years, cases of severe and high-level P. vivax parasitemia have been reported, challenging assumption that all isolates are equally restricted. this article, we analyze reticulocyte preference a large number Indian isolates. Our results show significantly vary in their level preference. addition, by carefully staging parasites, find schizonts...